Antiallergic asthma effect of trans-4-guanidinomethylcyclohexane-carboxylic
acid p-tert-butylphenyl
ester hydrochloride (NCO-650), a new
anti-allergic drug, was investigated in comparison with those of
tranilast and
disodium cromoglycate (DSCG) in anesthetized dogs. The asthmatic bronchoconstriction was induced by inhalation of Ascaris suum
antigen (Asc-Ag) to naturally Ascaris-sensitive dogs. The airway resistance was determined using the modified Konzett-Rössler method. Both intravenous (1 and 5 mg/kg) and intraduodenal (10, 30 and 100 mg/kg) administrations of
NCO-650 prior to the
antigen challenge markedly inhibited the asthmatic bronchoconstriction induced by Asc-Ag inhalation. The
antiasthmatic effect of
NCO-650 was much stronger than that of DSCG (10 mg/kg, i.v.) and was about three-fold stronger than that of
tranilast. On the other hand, when
NCO-650 was administered after the
antigen challenge, the agent had no inhibitory effect on the Asc-Ag induced bronchoconstriction. As for the effects on increased airway secretion at the time of asthmatic attack,
NCO-650 inhibited the excessive secretions without any remarkable change in the viscosity of the secretions.
NCO-650 had no effect on the bronchoconstriction induced by inhalation of
acetylcholine, suggesting that
NCO-650 appears to have no
anti-cholinergic effect and thus no effect on the vagal reflex that occurred during the asthmatic responses. The above findings show that
NCO-650 may be useful for the treatment of
bronchial asthma as an orally active
drug.